These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1717981)

  • 21. Substitution of the erbB-2 oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin and insulin-receptor substrate 1.
    Cheatham B; Shoelson SE; Yamada K; Goncalves E; Kahn CR
    Proc Natl Acad Sci U S A; 1993 Aug; 90(15):7336-40. PubMed ID: 7688476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active.
    Yarden Y
    Proc Natl Acad Sci U S A; 1990 Apr; 87(7):2569-73. PubMed ID: 1969636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
    Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG; Ethier SP
    Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells.
    Marte BM; Jeschke M; Graus-Porta D; Taverna D; Hofer P; Groner B; Yarden Y; Hynes NE
    Mol Endocrinol; 1995 Jan; 9(1):14-23. PubMed ID: 7760847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Down-regulation of cellular platelet-derived growth factor receptors induced by an activated neu receptor tyrosine kinase.
    Lehtola L; Nistér M; Hölttä E; Westermark B; Alitalo K
    Cell Regul; 1991 Aug; 2(8):651-61. PubMed ID: 1685673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function.
    Wada T; Qian XL; Greene MI
    Cell; 1990 Jun; 61(7):1339-47. PubMed ID: 1973074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical analysis of the ligand for the neu oncogenic receptor.
    Yarden Y; Peles E
    Biochemistry; 1991 Apr; 30(14):3543-50. PubMed ID: 1672825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repression of neu-induced clonogenicity by dimethylsulfoxide correlates with decreased levels of neu-encoded cell-surface p185 and changes in phosphotyrosine content of endogenous proteins.
    Matin A; Hung MC
    Cancer Lett; 1993 Jan; 68(1):55-60. PubMed ID: 7678546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy.
    Stancovski I; Peles E; Ben Levy R; Lemprecht R; Kelman Z; Goldman-Michael R; Hurwitz E; Bacus S; Sela M; Yarden Y
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):95-103. PubMed ID: 1356018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract.
    Cohen JA; Weiner DB; More KF; Kokai Y; Williams WV; Maguire HC; LiVolsi VA; Greene MI
    Oncogene; 1989 Jan; 4(1):81-8. PubMed ID: 2563577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.
    Zhang L; Lau YK; Xi L; Hong RL; Kim DS; Chen CF; Hortobagyi GN; Chang C; Hung MC
    Oncogene; 1998 Jun; 16(22):2855-63. PubMed ID: 9671406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
    Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
    Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.
    Mikami Y; Davis JG; Dobashi K; Dougall WC; Myers JN; Brown VI; Greene MI
    Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7335-9. PubMed ID: 1354355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of distinct populations of PI-3 kinase activity following T-cell activation.
    Thompson PA; Gutkind JS; Robbins KC; Ledbetter JA; Bolen JB
    Oncogene; 1992 Apr; 7(4):719-25. PubMed ID: 1373484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Downregulation of the early genomic growth factor response in neu oncogene-transformed cells.
    Sistonen L; Koskinen PJ; Lehväslaiho H; Lehtola L; Bravo R; Alitalo K
    Oncogene; 1990 Jun; 5(6):815-21. PubMed ID: 1972791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An extra cysteine proximal to the transmembrane domain induces differential cross-linking of p185neu and p185neu.
    Cao H; Bangalore L; Dompé C; Bormann BJ; Stern DF
    J Biol Chem; 1992 Oct; 267(28):20489-92. PubMed ID: 1356980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.
    Stern DF; Kamps MP; Cao H
    Mol Cell Biol; 1988 Sep; 8(9):3969-73. PubMed ID: 2464744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the neu proto-oncogene by Schwann cells during peripheral nerve development and Wallerian degeneration.
    Cohen JA; Yachnis AT; Arai M; Davis JG; Scherer SS
    J Neurosci Res; 1992 Apr; 31(4):622-34. PubMed ID: 1374476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
    Zhang HT; O'Rourke DM; Zhao H; Murali R; Mikami Y; Davis JG; Greene MI; Qian X
    Oncogene; 1998 Jun; 16(22):2835-42. PubMed ID: 9671404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.